Latest From Cochlear Ltd.
The proceeds from the investment will enable Nyxoah to prepare for the IDE pivotal trial of the Genio system in the US, and accelerate market access and commercialization activities in Europe, Australia and New Zealand.
A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker, including a PMA supplement for Agilent’s PD-L1 IHC 22C3 pharmDx companion diagnostic for Merck’s Keytruda (pembrolizumab), an anti-PD-1 drug, for patients with head and neck squamous cell carcinoma. The US FDA also approved a supplement for the Cochlear Nucleus Profile Plus Series Cochlear Implant, designed to be safe with magnetic resonance imaging.
Cochlear Ltd. has formed an alliance with French biotech company Sensorion to explore if a combination drug/hearing implant can improve the treatment of hearing loss. The collaboration moves Cochlear outside of its device field and could see it obtain a global license for Sensorion's SENS-401 drug candidate.
This month's edition of Device Debuts includes new product launches from Medtronic, Cochlear, Qualcomm, Titan Spine, Stryker, Philips, Nuance, Nevro, Siemens, Vortex BioSciences, ResMed, Respircardia, and others.
- Implantable Devices
- Therapeutic Areas
- Otolaryngology > Deafness
- Parent & Subsidiaries
- Cochlear Ltd.
- Senior Management
Chris Roberts, PhD, Pres. & CEO
Neville Mitchell, CFO
Jan Janssen, SVP, Design & Dev.
Michael Kavanagh, SVP, Global Mktg.
- Contact Info
Phone: (61) 2 9428 6555
14 Mars Rd.
P.O. Box 629 Lane Cove, NSW 2066
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.